TCGA-GC-A6I3-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.350
- ALLOGRAFT_REJECTION+0.320
- OXIDATIVE_PHOSPHORYLATION+0.300
- INTERFERON_ALPHA_RESPONSE+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
- PANCREAS_BETA_CELLS+0.210
- DNA_REPAIR+0.190
- INTERFERON_GAMMA_RESPONSE+0.180
- MYC_TARGETS_V1+0.120
- APICAL_SURFACE+0.110
Top 10 suppressed
- TGF_BETA_SIGNALING-0.550
- PROTEIN_SECRETION-0.480
- UV_RESPONSE_DN-0.480
- MITOTIC_SPINDLE-0.450
- ANDROGEN_RESPONSE-0.430
- G2M_CHECKPOINT-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.340
- ESTROGEN_RESPONSE_EARLY-0.300
- ANGIOGENESIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.824 |
| 2 | 54f66d7c-b022-4df2-830d-48d55791c80e | — | — | 0.802 |
| 3 | TCGA-MT-A67A-01A-11R-A30B-07 | — | — | 0.788 |
| 4 | BS_TNRHHYNC | EPN | EPN Tumor | 0.787 |
| 5 | TCGA-BH-A0BT-01A-11R-A12P-07 | — | B | 0.773 |
| 6 | TCGA-49-AAQV-01A-11R-A39D-07 | — | cohortA1 | 0.772 |
| 7 | TCGA-GU-A763-01A-11R-A32O-07 | — | — | 0.767 |
| 8 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.766 |
| 9 | 5e2bb136-9a8b-4481-9394-d7eff1793f97 | — | — | 0.765 |
| 10 | TCGA-E2-A10C-01A-21R-A10J-07 | — | B | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| COAGULATION | 0.020 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |